Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven P Treon

Showing results (141-150 of 323) with videos related to

Pageof 33
Sort By:
British Journal of Haematology|January 14, 2015
The BCL2 antagonist ABT-199 triggers apoptosis, and augments ibrutinib and idelalisib mediated cytotoxicity in CXCR4 Wild-type and CXCR4 WHIM mutated Waldenstrom macroglobulinaemia cellsYang Cao, Guang Yang, Zachary R Hunter, et al.
Blood|November 16, 2002
CD40 induces human multiple myeloma cell migration via phosphatidylinositol 3-kinase/AKT/NF-kappa B signalingYu-Tzu Tai, Klaus Podar, Nicholas Mitsiades, et al.
Seminars in Oncology|April 30, 2003
Treatment recommendations in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's MacroglobulinemiaMorie A Gertz, Athanasios Anagnostopoulos, Kenneth Anderson, et al.
Clinical Lymphoma & Myeloma|April 14, 2009
Balancing risk versus benefit in the treatment of Waldenström's Macroglobulinemia patients with nucleoside analogue-based therapyXavier Leleu, Jérome Tamburini, Aldo Roccaro, et al.
British Journal of Haematology|April 14, 2016
Targeting Myddosome Assembly in Waldenstrom MacroglobulinaemiaXia Liu, Zachary R Hunter, Lian Xu, et al.
Cancer Research|October 30, 2003
Fluorescence imaging of multiple myeloma cells in a clinically relevant SCID/NOD in vivo model: biologic and clinical implicationsConstantine S Mitsiades, Nicholas S Mitsiades, Ron T Bronson, et al.
Seminars in Hematology|April 26, 2023
Report of Consensus Panel 6 from the 11 th International Workshop on Waldenström's Macroglobulinemia on Management of Waldenström's Macroglobulinemia Related AmyloidosisGiampaolo Merlini, Shayna Sarosiek, Giulia Benevolo, et al.
American Journal of Hematology|March 7, 2026
Venetoclax or Pirtobrutinib in Relapsed/Refractory Waldenström Macroglobulinemia: Clinical and Molecular Predictors and Sequencing ImplicationsAlberto Guijosa, Nickolas Tsakamaklis, Margaret Kobs, et al.
Blood|January 12, 2011
Hyperphosphorylated paratarg-7: a new molecularly defined risk factor for monoclonal gammopathy of undetermined significance of the IgM type and Waldenstrom macroglobulinemiaSandra Grass, Klaus-Dieter Preuss, Alexandra Wikowicz, et al.
British Journal of Haematology|July 30, 2016
Renal disease related to Waldenström macroglobulinaemia: incidence, pathology and clinical outcomesJosephine M Vos, Joshua Gustine, Helmut G Rennke, et al.
Pageof 33

Showing results (141-150 of 323) with videos related to

Sort By:
Pageof 33
British Journal of Haematology|January 14, 2015
The BCL2 antagonist ABT-199 triggers apoptosis, and augments ibrutinib and idelalisib mediated cytotoxicity in CXCR4 Wild-type and CXCR4 WHIM mutated Waldenstrom macroglobulinaemia cellsYang Cao, Guang Yang, Zachary R Hunter, et al.
Blood|November 16, 2002
CD40 induces human multiple myeloma cell migration via phosphatidylinositol 3-kinase/AKT/NF-kappa B signalingYu-Tzu Tai, Klaus Podar, Nicholas Mitsiades, et al.
Seminars in Oncology|April 30, 2003
Treatment recommendations in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's MacroglobulinemiaMorie A Gertz, Athanasios Anagnostopoulos, Kenneth Anderson, et al.
Clinical Lymphoma & Myeloma|April 14, 2009
Balancing risk versus benefit in the treatment of Waldenström's Macroglobulinemia patients with nucleoside analogue-based therapyXavier Leleu, Jérome Tamburini, Aldo Roccaro, et al.
British Journal of Haematology|April 14, 2016
Targeting Myddosome Assembly in Waldenstrom MacroglobulinaemiaXia Liu, Zachary R Hunter, Lian Xu, et al.
Cancer Research|October 30, 2003
Fluorescence imaging of multiple myeloma cells in a clinically relevant SCID/NOD in vivo model: biologic and clinical implicationsConstantine S Mitsiades, Nicholas S Mitsiades, Ron T Bronson, et al.
Seminars in Hematology|April 26, 2023
Report of Consensus Panel 6 from the 11 th International Workshop on Waldenström's Macroglobulinemia on Management of Waldenström's Macroglobulinemia Related AmyloidosisGiampaolo Merlini, Shayna Sarosiek, Giulia Benevolo, et al.
American Journal of Hematology|March 7, 2026
Venetoclax or Pirtobrutinib in Relapsed/Refractory Waldenström Macroglobulinemia: Clinical and Molecular Predictors and Sequencing ImplicationsAlberto Guijosa, Nickolas Tsakamaklis, Margaret Kobs, et al.
Blood|January 12, 2011
Hyperphosphorylated paratarg-7: a new molecularly defined risk factor for monoclonal gammopathy of undetermined significance of the IgM type and Waldenstrom macroglobulinemiaSandra Grass, Klaus-Dieter Preuss, Alexandra Wikowicz, et al.
British Journal of Haematology|July 30, 2016
Renal disease related to Waldenström macroglobulinaemia: incidence, pathology and clinical outcomesJosephine M Vos, Joshua Gustine, Helmut G Rennke, et al.
Pageof 33